Floatz logo

VINCRISTINE SULFATE

Mature B-Cell Malignancies

BeOne MedicinesSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Mature B-Cell Malignancies cohort.

Asset / SponsorPhaseRating
Zanubrutinib
BeOne Medicines
Phase 1/2B
PREDNISONE TABLETS
BeOne Medicines
Phase 1/2B
Sonrotoclax
BeOne Medicines
Phase 1CC
Obinutuzumab
BeOne Medicines
Phase 1CC

Same molecule, other indications

VINCRISTINE SULFATE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
diffuse large B-cell lymphomaDormant
A
Indicative ·
80 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →